We are live on ! Find out more
HKPD icon

Cellyan Biotechnology

9 hedge funds and large institutions have $78.6K invested in Cellyan Biotechnology in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

21,389% more capital inflows, than outflows

Capital inflows: $88.3K | Capital outflows: $411

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

50% more funds holding

Funds holding: 6 → 9 (+3)

2.55% more ownership

Funds ownership: 2.23% → 4.78% (+2.5%)

Holders
9
Holders Change
+3
Holders Change %
+50%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$411

HKPD Hedge Fund Activity: Q3 2026 in Review

9 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q3 2026, worth a combined $78.6K — down 26% from $106K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new HKPD positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was XTX Topco, adding an estimated $29.1K. The largest seller was UBS Group, exiting entirely with an estimated $411 sold.

  • 9 institutional investors held Cellyan Biotechnology (HKPD) as of Q3 2026, up from 6 in Q2 2026.
  • Funds reported $78.6K of Cellyan Biotechnology stock for Q3 2026, down 26% quarter-over-quarter.
  • 4 funds opened new Cellyan Biotechnology positions in Q3 2026 and 1 closed out, a net change of +3 holders.
  • The largest Cellyan Biotechnology buyer in Q3 2026 was XTX Topco, an estimated $29.1K added.
  • The largest Cellyan Biotechnology seller in Q3 2026 was UBS Group, an estimated $411 sold.

Based on aggregated 13F filings for Q3 2026.